Microtubule Affinity-regulating Kinase 2 (MARK2) Turns on Phosphatase and Tensin Homolog (PTEN)-induced Kinase 1 (PINK1) at Thr-313, a Mutation Site in Parkinson Disease

**EFFECTS ON MITOCHONDRIAL TRANSPORT**

Dorthe Matenia, Cindy Hemp, Thomas Timm, Annika Eikhof, and Eva-Maria Mandelkow

From the Max Planck Unit for Structural Molecular Biology, c/o Deutsches Elektronen Synchrotron (DESY), Notkestrasse 85, 22607 Hamburg, Germany and Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) (German Center for Neurodegenerative Diseases) and Center of Advanced European Studies and Research (CAESAR), 53175 Bonn, Germany

**Background:** Deregulation of protein kinases MARK2 and PINK1 has been linked to neurodegenerative diseases.

**Results:** MARK2 was identified as an upstream regulator of PINK1.

**Conclusion:** The MARK2-PINK1 cascade provides new insights into the regulation of mitochondrial trafficking in neurons.

**Significance:** This protein kinase signaling axis might provide a link between neurodegenerative processes in Alzheimer and Parkinson diseases.

The kinase MARK2/Par-1 plays key roles in several cell processes, including neurodegeneration such as Alzheimer disease by phosphorylating tau and detaching it from microtubules. In search of interaction partners of MARK2, we identified phosphatase and tensin homolog (PTEN)-induced kinase 1 (PINK1), which is important for the survival of neurons and whose mutations are linked to familial Parkinson disease (PD). MARK2 phosphorylated and activated the cleaved form of PINK1 (ΔN-PINK1; amino acids 156–581). Thr-313 was the primary phosphorylation site, a residue mutated to a non-phosphorylatable form (T313M) in a frequent variant of PD. Mutation of Thr-313 to Met or Glu in PINK1 showed toxic effects with abnormal mitochondrial distribution in neurons. MARK2 and PINK1 were found to colocalize with mitochondria and regulate their transport. ΔN-PINK1 promoted anterograde transport and increased the fraction of stationary mitochondria, whereas full-length PINK1 promoted retrograde transport. In both cases, MARK2 enhanced the effects. The results identify MARK2 as an upstream regulator of PINK1 and ΔN-PINK1 and provide insights into the regulation of mitochondrial trafficking in neurons and neurodegeneration in PD.

Transport of vesicles and organelles is vital for cells, especially in neurons. Tau and other microtubule-associated proteins promote the assembly and stabilization of neuronal microtubule tracks and ensure microtubule-dependent transport. We showed previously that elevated tau leads to inhibition of traffic because of competition with motor proteins for microtubule binding. This inhibition can be relieved by MARK2, which phosphorylates microtubule-associated proteins and causes their detachment from microtubules. Consequently, MARK2 has a pivotal role in the regulation of microtubule dynamics and cellular transport.

Kinases of the MARK/Par-1 family perform diverse functions in neuronal polarity, transport, migration, and neurodegeneration. MARK2 activity can be inhibited by complex formation (e.g. with PAK5) or intramolecular interactions between domains. In view of the importance of MARK for neuronal polarity and neurodegeneration, we set out to identify novel partners of MARK2 and herein describe the interaction of MARK2 with ΔN-PINK1 (aa 156–581)/full-length PINK1 (PINK1**Δ**15) and the effects of these kinases on mitochondrial transport and distribution.

PINK1 is a mitochondrially targeted serine/threonine kinase that promotes cell survival, particularly under conditions of oxidative/metabolic stress. PINK1 mutations are linked to PD and mostly result in loss of kinase activity. The molecular events responsible for neuronal death as well as physiological substrates or regulators of PINK1 are currently a matter of debate. The mitochondrial localization of PINK1 and alterations in mitochondrial morphology, dynamics, and function caused by PINK1 deficiency implicate a central role of PINK1 in normal mitochondrial function. The location of PINK1 in the mitochondrial intermembrane space, the outer mitochondrial membrane. The abbreviations used are: MARK, microtubule-associated protein/microtubule affinity-regulating kinase; CFP, cyan fluorescent protein; FL, full-length; MTS, mitochondrial targeting sequence; PD, Parkinson disease; PINK1, PTEN-induced kinase 1; PTEN, phosphatase and tensin homolog; RGC, retinal ganglion cell.
membrane (21, 22), or even the cytoplasm (15, 23). Other data support a model in which PINK1 spans the outer mitochondrial membrane with the N-terminal end inside the mitochondria and the C-terminal kinase domain facing the cytosol (24). This topology relies on a transmembrane domain located just after the mitochondrial targeting sequence (MTS) of PINK1 and allows substrate phosphorylation outside of the mitochondria. However, PINK1 protein is cleaved upon entry into the mitochondria to produce two N-terminally truncated protein fragments of 54 and 45 kDa (12) that localize more to the cytosolic than to the mitochondrial fraction (25). This suggests that cytosolic targets and signal transduction pathways may be modified by cleaved PINK1 to affect neuronal survival (23). The physiological function of these truncated PINK1 proteins is still unknown, although ΔN-PINK1 is quite stable, indicating that this is one of the predominant forms in the steady state (25). Here, we show that MARK2 interacted with and phosphorylated preferentially the 45-kDa fragment (termed ΔN-PINK1), thereby increasing its kinase activity. Both kinases colocalized with mitochondria in primary neurons, especially in the growth cone, and modified mitochondrial transport. The main site phosphorylated by MARK2 on ΔN-PINK1 was Thr-313, a frequent mutation site (T313M) in certain forms of familial PD (26). This suggests that failure of the MARK2-PINK1 signaling cascade contributes to the disease.

EXPERIMENTAL PROCEDURES

Plasmids—The full-length cDNA clone PINK1 wild-type (WT) pCMV-Sport6 was obtained from the RZPD (Ressourcenzentrum Primärdatenbank, Berlin, Germany). PINK1FL was amplified by PCR using oligonucleotides that introduce an NdeI restriction site at the start codon and an Nhel restriction site behind the stop codon. The 45-kDa fragment ΔN-PINK1 was chosen to include residues 156–581 because this corresponds closely to the cellular fragment (whose exact cleavage site is not known (27)). The fragment was cloned into pEU-myc and examined by sequencing. PINK1 deletion and point mutants (e.g. ΔN-PINK1, aa 156–581) were generated by PCR using primers containing appropriate mutations and restriction sites. All PINK1-YFP constructs were generated by PCR using oligonucleotides that introduce a HindIII restriction site at the start codon and an Nhel restriction site behind the stop codon of the PINK1 sequence. The fragment was cloned into the YFP-pShuttle fluorescence expression vector to generate adenovirus. PINK1 deletion and point mutants were generated using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) and primers containing the appropriate sequence and point mutations. The cloning of MARK2-pGBKKT7 constructs was reported previously (6). All sequences generated by PCR were verified by DNA sequencing.

Yeast Two-hybrid Analysis—The yeast two-hybrid screen and direct binding assays were performed according to the manufacturer’s instructions for the MATCHMAKER GAL4 Two-Hybrid System (Clontech) and were described previously (6).

Protein Purification—Recombinant PINK1FL-pVL-His was expressed in SF9 cells using the baculovirus system BaculoGold (BD Pharmingen). Recombinant GST-ΔN-PINK1, GST-ΔN-PINK1T313A, GST-ΔN-PINK1T313E, and His-MARK2 were expressed in Escherichia coli (BL21 DE3pLys; Merck) and purified with a nickel-nitritriacetic acid column (Qiagen, Hilden, Germany) for His-tagged proteins and with glutathione-Sepharose 4B beads (GE Healthcare) for GST-tagged proteins as described previously (3).

Immunoprecipitation and Immunoblot Analysis—Immunoprecipitation and immunoblot analysis were done by standard procedures as described previously (6).

Antibodies and Dyes—Antibodies, markers, immunofluorescence, and coupling methods are described in the supplemental Experimental Procedures.

Cell Fractionation—Preparations of mitochondrial fractions from N2A cells were kindly provided by A. M. Cuervo (Albert Einstein College, Bronx, NY) and are described elsewhere (29).

In Vitro Kinase Activity Assay—Purified PINK1 and MARK2 proteins were used at a concentration of 1 μM each. 150 μM histone H4 (Sigma-Aldrich) was used as a substrate for ΔN-PINK1. As substrate for MARK2, we used 150 μM TR1 peptide derived from the first repeat of tau protein containing the KAGS motif (30). The activity was assayed as described previously (3). Phosphorylated TR1 peptide was measured in a scintillation counter (Tricarb 1900 CA, Packard), and phosphorylated proteins were separated by SDS-PAGE and visualized by autoradiography using a bioimaging analyzer (BAS 3000, Raytest, Straubenhardt, Germany).

Preparation of in Vitro Phosphorylated PINK1 Peptides—The preparation of the in vitro phosphorylated PINK1 peptides is described in the supplemental Experimental Procedures.

Phosphopeptide Mapping—Two-dimensional phosphopeptide mapping was performed on thin-layer cellulose plates (Macherey-Nagel, Düren, Germany) according to Boyle et al. (31). Peptides were separated in the first dimension by electrophoresis at pH 1.9 in 88% formic acid, acetic acid, water (50:156:1200) and in the second dimension by thin-layer chromatography in n-butyl alcohol/pyridine/acetic acid/water (150:100:30:120, pH 3.5).

Mass Spectrometry—MALDI-TOF mass spectrometry was performed on a Voyager-DE STR time-of-flight instrument (Applied Biosystems, Darmstadt, Germany) equipped with a nitrogen laser operating at 337 nm. The peptides were analyzed in a positive ion delayed extraction reflector mode using α-cyano-4-hydroxycinnamic acid (Sigma-Aldrich) (10 mg/ml in 0.05% TFA with 50% acetonitrile) as the UV light-absorbing matrix. Samples were dissolved in matrix solution and spotted onto the target plate, allowing them to air dry. All mass spectra were externally calibrated with standard peptides (New England Biolabs, Frankfurt, Germany) containing angiotensin, neurotensin, and various ACTH fragments. All spectra were analyzed using Data Explore™ software (Applied Biosystems).
**MARK2 and PINK1 Regulate Mitochondrial Transport**

Cell Culture—Cell culture was performed with HEK293, CHO, PC12, and SH cells following standard protocols at 37 °C with 5% CO₂. Details are described in the supplemental experimental procedures.

Immunostaining, Labeling, and Live Cell Light Microscopy—Cells were fixed in 3.7% paraformaldehyde for 15 min at room temperature. Cells were then washed twice with PBS to remove paraformaldehyde. Afterward, cells were permeabilized with 80% ice-cold methanol for 5 min at ~20 °C and washed three times with PBS. Cells were incubated with primary antibody for 1 h at 37 °C after blocking with 10% goat serum for 30 min at 37 °C to avoid unspecific binding. Cells were washed three times before incubating with fluorescence-labeled secondary antibody for 1 h at 37 °C. Cells were then mounted with PermaFluor (Beckman Coulter, Krefeld, Germany) and observed with a 63x oil immersion objective on an LSM510 Meta confocal microscope (Zeiss, Jena, Germany) using lasers, beam splitters, and filters according to the fluorophores. For time lapse imaging of mitochondria, cells were plated on glass bottom dishes. Cells were kept at 37 °C by air heating and supplied with 5% CO₂. Images were taken every 2–15 s adapted to the best experimental settings for tracking of mitochondria using a 63x objective, beam path, and laser settings for Cy5 for mitochondrial observation and YFP and CFP for confirming transfection of retinal ganglion cells (RGCs).

Data Analysis—The Zeiss LSM510 Image Browser software was used to track individual particles. We interpreted all stained mitochondria that were transported toward the axonal growth cone as anterograde and those that moved to the cell body as retrograde. Kymographs were then generated and analyzed using ImageJ Kymograph. The observation time varied from 5 to 10 min. To subtract the contribution from random Brownian motions, a mitochondrion was considered as actively transported if its velocity was faster than 0.3 μm/s (32). The following parameters were measured: velocity ν (μm/s), distance of transport (run length L; μm), direction (anterograde or retrograde), and pausing time. Mitochondria with velocities below 0.3 μm/s were defined to be pausing. If a mitochondrion stood idle for more than 80 s it was classified as stationary. Each movement (anterograde, retrograde, pause, or stationary) was counted as one independent value. For each transfection, three independent movies were evaluated. The averages were analyzed for statistical significance by one- or two-way analysis of variance. N indicates the number of experiments, and n is the number of observed mitochondrial movements. p values of <0.05, <0.01, and <0.001 are indicated with one, two, or three asterisks, respectively.

RESULTS

Identification of PINK1 as MARK2-interacting Protein—To identify new regulators or alternative substrates of MARK2, a human fetal brain cDNA library was screened using the MATCHMAKER yeast two-hybrid system. The bait was obtained by cloning the complete coding sequence of a kinase-dead MARK2 cDNA mutant into the two-hybrid vector. The MARK2T208A/S212A mutation was chosen because it mimics the unphosphorylated state of the kinase and keeps the substrate cleft in an open conformation (3, 8). Positive clones were further analyzed by DNA sequencing. One insert contained the DNA encoding part of the PINK1 kinase domain (aa 320–449). This suggested a possible interplay between these kinases in neurodegeneration because mutations in PINK1 are related to early onset Parkinsonism (33), and MARK2 is implicated in Alzheimer disease (2).

![Figure 1](http://example.com/figure1.png)

**Figure 1. Interaction between MARK2 and PINK1.** A, mapping the interaction domains of MARK2 and PINK1 by direct yeast two-hybrid tests. Constructs are shown schematically, amino acids are in parentheses, and domains are distinguished by different shades. N, N-terminal header domain; CAT, catalytic domain; UBA, ubiquitin-associated domain; KA1, kinase-associated domain 1; TM, putative transmembrane domain. Results of the two-hybrid analysis are indicated by ++ (very strong interaction), + (strong), + (weak), and — (no interaction). Note that both kinases interact via their catalytic domains. B, interaction of the kinases MARK2 and ΔN-PINK1 via their catalytic domains. The putative cleavage site 1 (I) between aa 76 and 77 and site 2 (II) between aa 156 and 157 in PINK1 are indicated by scissors. Cleavage at aa 76/77 results in the 54-kDa fragment, and cleavage at aa 156/157 results in the 45-kDa ΔN-PINK1 fragment. C, HEK293 cells were transfected with plasmids encoding ΔN-PINK1-myc, PINK1FL/T313M, HA-MARK2WT, or HA-MARK2T208A/S212A (inactive mutation) either singly (lanes 2-4 and 7 and 8) or in combination (lane 5, 6, and 9). Empty pEU vector (lane 1) was used to make the total amount of transfected DNA equivalent. Cell lysates were immunoprecipitated with anti-HA antibody (row 3) and immunoblotted either with anti-HA antibody (row 1, WB: MARK2) or anti-myc antibody (rows 2 and 3, WB: PINK1), ΔN-PINK1 immunoprecipitates more strongly with the inactive MARK2 mutant than with MARK2WT, probably due to altered conformation after activation. In the case of PINK1T313M, only a non-phosphorylatable form (T313M) binds sufficiently well to MARK2T208A/S212A.



8176 JOURNAL OF BIOLOGICAL CHEMISTRY

VOLUME 287 • NUMBER 11 • MARCH 9, 2012
MARK2 and PINK1 Regulate Mitochondrial Transport

checked in combination with the detected PINK1 fragment in direct two-hybrid interaction tests to map the binding domains of the kinases (Fig. 1A). Both proteins interact via their kinase domains (Fig. 1B). The C-terminal domain of MARK2 is not involved in binding the PINK1 fragment (aa 320–449) because this domain alone showed no interaction with the PINK1 construct. To confirm the results of the direct two-hybrid tests, a coimmunoprecipitation using HEK293 cells was carried out (Fig. 1C). We generated ΔN-PINK1 (residue 156–581) and different mutants to study its activity and interactions in the absence of possible influence by its adjacent domains (34). This construct corresponds closely to the most stable 45-kDa PINK1 cleavage product (25). We coexpressed wild-type or kinase-dead HA-tagged MARK2 in combination with ΔN-PINK1 or PINK1FL. When lysates of these cells were immunoprecipitated with anti-HA antibody, ΔN-PINK1 was detected in the HA-MARK2 immune complexes (Fig. 1C, row 3). The interaction with kinase-dead MARK2 was stronger than with MARK2WT, indicating that conformational changes of MARK2 in its activation loop may enhance the binding to ΔN-PINK1. An interaction of PINK1FL and MARK2WT alone was not detectable by coimmunoprecipitation (data not shown). However, coexpression of kinase-dead HA-tagged MARK2 and a non-phosphorylatable form of PINK1FL (T313M mutant) led to binding of both kinases detectable by coimmunoprecipitation (Fig. 1C, row 3, lane 9), suggesting that the phosphorylation reaction modulates the strength of the interaction (for further details, see Figs. 3 and 4).

To examine the subcellular localization of MARK2 and ΔN-PINK1, primary rat cortical neurons were transfected with ΔN-PINK1-YFP and CFP-MARK2T208A/S212A by adenovirus and analyzed by immunofluorescence (Fig. 2). Both kinases have a vesicular appearance in axons and dendrites and a mainly cytoplasmic distribution in the cell soma. A strong colocalization was visible particularly in vesicle-like structures, confirming the two-hybrid and coimmunoprecipitation data (Figs. 2 and 4–6). Cortical neurons transfected with PINK1FL and MARK2WT showed partial colocalization due to different expression patterns of PINK1FL and ΔN-PINK1 (Figs. 2 and 7–9). PINK1FL was more localized in the cell soma and to a lesser extent in axons and dendrites.

MARK2 Phosphorylates ΔN-PINK1 at Thr-313 and Enhances Its Activity—Because the catalytic domains of the two kinases interact with one another, the question arose whether this influences their kinase activities. To examine this possibility, we performed in vitro phosphorylation assays to test the ability of MARK2 to phosphorylate PINK1FL or ΔN-PINK1 and vice versa. First, bacterially purified PINK1FL or ΔN-PINK1, alone or in combination with MARK2WT, and constitutively active MARK2T208E (3) were incubated with [32P]ATP. PINK1FL or MARK2WT alone showed only slight autophosphorylation (Fig. 3A, lanes 1 and 4) that became strong in the case of MARK2T208E (Fig. 3A, lane 3). ΔN-PINK1 revealed no autophosphorylation (Fig. 3A, lane 2), but in combination with MARK2T208E, it was strongly phosphorylated (Fig. 3A, lane 6 and bar 6). The effect on PINK1FL was weak (Fig. 3A, bar 5), indicating a strong preference of MARK2 for the cleaved (cytoplasmic) ΔN-PINK1 or a conformational hindrance of PINK1FL in vitro. However, the results of the coimmunoprecipitation experiment with MARK2T208A/S212A and the non-phosphorylatable PINK1FL mutant indicate that MARK2 binds to the mutant but cannot complete the phosphorylation reaction in this situation.
To investigate the functional consequences of the phosphorylation of \( \text{PINK1} \) by MARK2, we first identified the phosphorylation sites by phosphopeptide mapping followed by mass spectrometry. Constitutively active MARK2T208E and \( \text{PINK1} \) were incubated with \([32P]\)ATP. Phosphorylated \( \text{PINK1} \) was separated by SDS-PAGE followed by tryptic in-gel digestion and phosphopeptide enrichment. These peptides were mapped by thin-layer electrophoresis (horizontal) followed by thin-layer chromatography (vertical). The main spot shown in Fig. 3B corresponds to phosphorylated Thr-313 of \( \text{PINK1} \) peptides identified by MALDI-TOF MS analysis. The minor spots are in accordance with phosphorylated Thr-333 and Ser-335 of \( \text{PINK1} \) peptides. Because T313M is known as a frequent PD-associated mutation in the kinase domain of \( \text{PINK1} \) (26), this residue may have an important function in the regulation of \( \text{PINK1} \). The Thr-313, which is phosphorylated by MARK2, is located in \(-\text{strand 5} \) (green). Phosphorylation of this residue likely results in the interaction of strand 5 with helix C or its insert, thus stabilizing helix C. This helix is part of the scaffold that fixes the Mg-ATP underneath the P-loop and is a requirement for the activity of the kinase.

Because mutation of threonine to alanine prevents further phosphorylation/activation, whereas mutation to phosphorylation-mimicking glutamate produces active forms of many kinases (5), several \( \text{PINK1} \) mutants were created replacing Thr-313 to confirm the specificity of this newly identified phosphorylation site. Bacterially purified \( \text{PINK1} \) was incubated alone or in combination with MARK2T208E in the presence of \([32P]\)ATP. Indeed, this mutation caused a reduction (\( \approx 60\% \)) of the phosphorylation of \( \text{PINK1} \) by active MARK2, but phosphorylation of \( \text{PINK1} \) still occurred, indicating that MARK2 also phosphorylates other sites of the kinase (Fig. 4A, compare lanes 7 and 8). Although Thr-313 was mutated to glutamate in \( \text{PINK1} \), MARK2T208E increased further the phosphorylation by 67% in comparison with the approach with non-mutated \( \text{PINK1} \). This led to the assumption that Thr-313 is a “priming” phosphorylation site to prepare the ground for further phosphorylation of \( \text{PINK1} \).
To clarify whether this strong phosphorylation of ΔN-PINK1 by MARK2\textsuperscript{T208E} influences the activity of ΔN-PINK1, phosphorylation assays using the artificial PINK1 substrate histone H4 were performed (34). The results indicate that MARK2\textsuperscript{T208E} alone phosphorylates histone H4 only slightly (Fig. 4B, bar 5), but in combination with ΔN-PINK1, the substrate phosphorylation was enhanced (Fig. 4B, bar 7), indicating that MARK2 stimulates the kinase activity of ΔN-PINK1. ΔN-PINK1\textsuperscript{T313E} was not constitutively active (Fig. 4B, bar 3), but MARK2\textsuperscript{T208E} induced a 2.5-fold higher activation of the Glu mutant in comparison with the batch with non-mutated ΔN-PINK1 (Fig. 4B, bar 8). Accordingly, the ΔN-PINK1\textsuperscript{T313A} mutant was not completely kinase-dead, but the activation could not be further enhanced by MARK2\textsuperscript{T208E} in comparison with the non-mutated ΔN-PINK1 (Fig. 4B, bars 7 and 9). These results prove that phosphorylation of Thr-313 is important but not sufficient for full activation of ΔN-PINK1.

To exclude the possibility that MARK2 is activated by ΔN-PINK1 and thus causes the enhanced phosphorylation of histone, the kinase activity of MARK2 was measured by its phosphorylation of the tau peptide TR1 (derived from the first repeat sequence of tau protein (30)). Constitutively active MARK2\textsuperscript{T208E} and PINK1\textsuperscript{FL} or ΔN-PINK1 were mixed together with the TR1 peptide and incubated with \[^{32}P\]ATP, and MARK2 activity was measured by the phosphorylation of TR1 using a scintillation counter. There was a ~30–40\% inhibition of MARK2 activity induced by PINK1\textsuperscript{FL} or ΔN-PINK1 possibly due to binding of PINK1\textsuperscript{FL} and ΔN-PINK1 (Fig. 4C, bars 4 and 5). A similar inhibitory mechanism was shown previously with MARK2 and PAK5 (6). PINK1\textsuperscript{FL} also reduced MARK2 activity, although the MARK2-induced phosphorylation of PINK1\textsuperscript{FL} was weak in vitro. To clarify whether PINK1\textsuperscript{FL} is linked to MARK2 directly or indirectly, a protein stability assay was performed. CHO cells were individually transfected with PINK1\textsuperscript{FL} alone or in combination with MARK2\textsuperscript{T208A/S212A} (Fig. 4D). At 16 h after the transfection, the cells were treated for 1 h with 10 μM epoxomycin (proteasome inhibitor) or 50 μM cycloheximide (inhibitor of protein biosynthesis). Both the proteasomal
MARK2 and PINK1 Regulate Mitochondrial Transport

Inhibitor and MARK2<sub>T208A/S212A</sub> increased the stability of full-length and cleaved PINK1, arguing for a physiological relevance of this kinase-substrate interaction. MARK2<sub>T208A/S212A</sub> stabilized particularly PINK1<sup>FL</sup> and the shortest cleaved PINK1 corresponding to our ΔN-PINK1 (Fig. 4D, row 1, lane 4). Additionally, a phosphorylation assay was carried out. CHO cells were transfected with ΔN-PINK1 or PINK1<sup>FL</sup> alone or in combination with MARK2<sup>T208E</sup>. PINK1 was immunoprecipitated, and phosphorylation was detected by immunoblotting with anti-phosphoserine or anti-phosphothreonine antibody. As expected, ΔN-PINK1 was mainly phosphorylated at threonine sites in a MARK2-dependent manner (supplemental Fig. S1, lane 5), whereas PINK1<sup>FL</sup> coexpressed with MARK2 showed phosphorylation at serine- and threonine-specific sites (supplemental Fig. S1, lane 6). These results confirmed our assumption that even PINK1<sup>FL</sup> is modified by MARK2. In summary, we identified MARK2 as an upstream activating kinase of PINK1.

**MARK2 Colocalizes with ΔN-PINK1 and Mitochondria in Primary Cortical Neurons**—Endogenous PINK1 occurs both in the cytoplasm and on mitochondria despite the mitochondrial localization signal in PINK1 (23). But ΔN-PINK1 can also be found at mitochondria (35, 36). Nevertheless, the exact localization is still a matter of debate. MARK2 is a cytoplasmic kinase, but we had shown earlier that MARK2 has a dotted distribution with a diffuse background, suggesting that it is partially associated with vesicles (6, 37) (Fig. 2). To study the localization of both kinases and to determine in which cell compartment the interaction of both kinases occurs, we initially stained endogenous active MARK2 in primary cortical neurons using a phosphospecific MARK2 antibody (MARK Thr(P)-208) and costained for mitochondria (Fig. 5A, panels 1–6). Surprisingly, we found an extensive colocalization (up to 80%) of MARK2 not only with vesicles but also with mitochondria, particularly in axons and dendrites, emphasized at the higher magnification (Fig. 5A, panels 4–6). To confirm this association, we performed fractionation experiments (Fig. 5B) using whole cell homogenate (lane 1) and cytoplasmic (lane 2) and mitochondrial fractions (lane 3) of N2A cells. The mitochondrial fraction was verified for purity by detection of the mitochondrial transmembrane voltage-dependent anion-selective channel/porin protein and the absence of actin (cytoplasmic component). Fig. 5B clearly shows that MARK staining occurs in the cytoplasmic fraction and in the mitochondrial fraction (lanes 2 and 3), suggesting a possible role of MARK2 in mitochondrial function. To characterize the linkage of MARK2, PINK1<sup>FL</sup>, ΔN-PINK1, and mitochondria, primary cortical neurons were transfected with adenoviral YFP-MARK2, PINK1<sup>FL</sup>-YFP, or ΔN-PINK1-YFP and stained for mitochondria. As mentioned above, high expression of MARK2 leads to phosphorylation of tau, breakdown of the microtubule network, and cell death. The adenoviral expression system was chosen because the protein expression is weak and in these conditions hardly toxic. Fig. 5C illustrates the distribution of mitochondria in neurites and cell bodies. In untransfected primary cortical neurons, the mitochondria are evenly spread out in axons and concentrated at axon roots in the cell body (Fig. 5C, panel 1). Neurons transfected with CFP-MARK2 or PINK1<sup>FL</sup>-YFP by adenovirus show nearly the same mitochondrial distribution as untransfected cells (Fig. 5C, panels 2–5). Conspicuously, neurons transfected with PINK1<sup>FL</sup> show the highest mitochondrial density in the initial part of axons (Fig. 5C, panel 5, arrow). Expression of ΔN-PINK1 leads to a clear change of the distribution of mitochondria: they accumulate partially in neurites or are retained in the cell body (Fig. 5C, panels 6 and 7, arrows), indicating a transport disorder. Taken together, these results show that PINK1<sup>FL</sup>, ΔN-PINK1, and MARK2 colocalize in part with mitochondria and potentially influence mitochondrial transport.

Cotransfection of MARK2 and PINK1<sup>FL</sup> enhanced the concentration of mitochondria in the cell body (consistent with an inhibition of anterograde transport; see below). By contrast, mitochondria in neurons transfected with MARK2 and ΔN-PINK1 show local accumulations in axons (Fig. 5C, panels 11–13, arrows). The transfection rate was low, and transfected neurons tend to degenerate. It seems that overexpression of both kinases is toxic for the cell, and transport of mitochondria is impaired.

**Movement of Mitochondria Is Perturbed in MARK2/ΔN-PINK1-transfected Retinal Ganglion Cells**—A proper mitochondrial localization is essential for neuronal function because of the high demand of energy, especially in active growth cones (38). Considering that MARK2 is involved in the regulation of microtubule-dependent transport (1) and that PINK1 is important for the anterograde transport of mitochondria along microtubules (36), we next investigated mitochondrial traffic in axons. Chicken RGCs were transfected with adenovirus encoding PINK1<sup>FL</sup> or ΔN-PINK1 and MARK2<sup>WT</sup> either alone or in combination. The advantage of these cells is that the polarities of the axons are well defined so that transport directions are readily analyzed. 20 h after transfection, the neurons were stained with marker dye reporting on total mitochondria. Control neurons display a uniform distribution of mitochondria in axons similar to neurons transfected with MARK2<sup>WT</sup> (Fig. 6A, panels 1 and 2). Likewise, PINK1<sup>FL</sup> is mainly colocalized with uniformly distributed mitochondria. By contrast, mitochondria in neurons transfected with ΔN-PINK1 are mostly accumulated in axonal swellings characteristic of degeneration (Fig. 6A, panel 5), indicating an inhibition of axonal transport. This effect was enhanced by cotransfection of ΔN-PINK1 in combination with MARK2<sup>WT</sup> (Fig. 6A, panel 6). Quantification of mitochondrial density revealed that the number of axonal mitochondria increases ~2-fold in ΔN-PINK1-transfected cells (Fig. 6B, bar 5) in comparison with controls (Fig. 6B, bar 1) or MARK2<sup>WT</sup>-transfected cells (Fig. 6B, bar 2) evaluated in the proximal 50 μm of the axons. The mitochondrial density in axons of PINK1<sup>FL</sup>-transfected cells dropped slightly (Fig. 6B, bar 3), and this effect was further enhanced by MARK2<sup>WT</sup> (Fig. 6B, bar 4). Cotransfection of ΔN-PINK1 with MARK2<sup>WT</sup> led to a much higher mitochondrial density compared with the effect of ΔN-PINK1 alone (Fig. 6B, bars 5 and 6), supporting the hypothesis of a MARK2<sup>WT</sup>/ΔN-PINK1-induced mitochondrial transport disorder.

Indeed, the change in distribution of mitochondria in axons corresponds to a change in mobility. We analyzed mitochondrial movement by live cell confocal microscopy. Untransfected cultures display the typical discontinuous saltatory movements.
MARK2 and PINK1 Regulate Mitochondrial Transport

Expression of ΔN-PINK1-YFP (yellow; panel 6) and staining for mitochondria (red; panel 7) show less mitochondria in neurites and additionally mitochondrial accumulation (arrow), indicating transport inhibition. Cotransfection of PINK1FL (yellow; panel 8) and MARK2WT (cyan; panel 9) reveals a main localization of mitochondria in the cell body (red; panel 10, arrow), whereas cotransfection of ΔN-PINK1 (yellow; panel 11) and MARK2WT (cyan; panel 12) leads to local accumulations of mitochondria in axons and dendrites (red; panel 13, arrows). Scale bars, 10 μm.

FIGURE 5. Subcellular localization of MARK in N2A cells and primary neurons. A, subcellular localization of endogenous active MARK2 and mitochondria was examined in primary rat cortex cells (E18). Neuronal cultures were stained for endogenous active MARK2 with the Thr(P)-208 antibody (cyan; panel 1) and mitochondria (red; panel 2). The kinase and the mitochondria are evenly distributed to the cell body, neurites, and growth cone and colocalize partially, especially in axons and dendrites (see magnification in panels 4–6). B, cytoplasmic and mitochondrial fractions or the whole cell homogenates of N2A cells were examined by the polyclonal MARK1–4 antibody SA4633 (raised against aa 1–377). The purity of the fractions was confirmed by Western blotting (WB) with anti-β-actin antibody (cytoplasmic marker) and the anti-voltage-dependent anion-selective channel (VDAC)/porin antibody (mitochondrial marker). MARK is found in the mitochondrial fraction (lane 3). C, subcellular distribution of mitochondria in primary rat cortex cells (E18). Untransfected and adenoviral CFP-MARK2WT-transfected neurons show normal and even distribution of mitochondria in neurites and soma (panels 1–3). Adenoviral transfection of the neurons with PINK1FL (yellow; panel 4) and staining for mitochondria show less mitochondria in the axon (red; panel 5). of mitochondria with pauses often followed by a reversal of direction (Fig. 7, A, panel 1, and C, bar 1). In the case of MARK2WT-, PINK1FL-, or ΔN-PINK1-transfected cells, the saltatory movements remain mostly intact (Fig. 7A, panels 2, 3, and 5). By contrast, in MARK2WT- and ΔN-PINK1-cotransfected cells, the movement of mitochondria was strongly inhibited. At 20 h after transfection, the mitochondria become mostly stationary (Fig. 7A, panel 6), whereas cotransfection of MARK2WT and PINK1FL had no influence on mitochondrial motion (Fig. 7A, panel 4).

For time periods of 10–20 min, we recorded the parameters of speed, run length, direction, pausing time, and their dependence on PINK1FL, ΔN-PINK1, and MARK2WT. Quantification showed that in control cells 20% of the stained particles are stationary (Fig. 7B, bar 1). The fraction of immobile mitochondria did not change significantly in PINK1FL-transfected cells (Fig. 7B, bar 3) and increased to ~35% in cells transfected with MARK2WT alone or PINK1FL in combination with MARK2WT (Fig. 7B, bars 2 and 4). A further increase of stationary mitochondria to ~45% can be observed in ΔN-PINK1-transfected cells (Fig. 7B, bar 5). This effect is boosted to ~76% in ΔN-PINK1 plus MARK2WT-transfected cells (Fig. 7B, bar 6). Thus, ΔN-PINK1 forces mitochondria to become stationary in cooperation with MARK2.

ΔN-PINK1 Promotes Anterograde and PINK1FL Promotes Retrograde Mitochondrial Transport, Both Depending on MARK2—The next question was whether the moving fraction of mitochondria displays changes in their transport direction dependent on PINK1FL, ΔN-PINK1, and MARK2 transfection. This was tested in adenoviral transfected retinal ganglion cell axons. Overall in control cultures, most of the mitochondria moved anterogradely (Fig. 7C, bar 1; ~70%). By contrast, in MARK2WT- or in PINK1FL-transfected cells the antero- and retrograde mitochondrial transport rates were nearly balanced with a slight excess of retrograde events (Fig. 7C, bars 2 and 3). Cotransfection of MARK2WT and PINK1FL strongly enhanced retrograde events to nearly 80% (Fig. 7C, bar 4, red box). However, in contrast to PINK1FL, ΔN-PINK1 reversed these effects and returned the ratio to the wild-type prevalence of anterograde movements, especially in the presence of MARK2WT (Fig. 7C, compare bars 1, 5, and 6). In summary, our data suggest that PINK1FL, ΔN-PINK1, and MARK2WT regulate the mitochondrial transport. PINK1FL pushes the balance toward retrograde movements, whereas ΔN-PINK1 promotes anterograde movements; in both cases, MARK2WT enhances these effects (illustrated by the anterograde/retrograde ratios in Fig. 7D, bars 4 and 6, red boxes). The enhancement of anterograde movements by ΔN-PINK1 is consistent with the observed mitochondrial accumulations and axonal swellings (see Fig. 6A, panels 5 and 6).
**MARK2 and PINK1 Regulate Mitochondrial Transport**



**FIGURE 6. Density of mitochondria in RGC axons 20 h after transfection with PINK1FL, ΔN-PINK1, or MARK2WT by adenovirus.** A, field of RGC axons either untransfected (Contr; panel 1) or adenoviral transfected with CFP-MARK2WT (panel 2), PINK1FL-YFP (panel 3), ΔN-PINK1-YFP (panel 5), or in combination with MARK2WT (panels 4 and 6) and stained for mitochondria. Untransfected and MARK2WT- or PINK1FL-transfected neurons show a normal and uniform distribution of mitochondria (panels 1–3). Mitochondria are frequent and tubular. By contrast, mitochondria in ΔN-PINK1-YFP-transfected neurons and even more in combination with MARK2WT show mitochondrial clustering/accumulation in swollen axons (panels 5 and 6). Scale bars, 10 μm. B, quantification of mitochondria measured in the proximal 50 μm of the axon. The number of mitochondria increases ∼2-fold in ΔN-PINK1-transfected cells (bar 5) compared with controls and MARK2WT-transfected cells (bars 1 and 2). This effect is further enhanced by coexpression of ΔN-PINK1 and MARK2WT (bar 6). PINK1FL-transfected and PINK1T313 and MARK2WT-transfected cells show a lower density of axonal mitochondria (bars 3 and 4). Significant differences are indicated (p < 0.05; N ≥ 5; n ≥ 100; two-way analysis of variance). Error bars show S.E. p values of <0.05 and <0.001 are indicated with one and three asterisks, respectively.

**Mutation of MARK2 Target Site Thr-313 in ΔN-PINK1 and PINK1FL Is Toxic in Primary Cortical and CHO Cells**—PINK1Thr-313 is frequently mutated in PD, and it is the main phosphorylation site of the upstream kinase MARK2. To clarify the importance of the site, we created different PINK1Thr-313 mutants and observed their subcellular localization as well as their effects on mitochondria in neuronal and CHO cells. Expression of PINK1T313E or PINK1T313M was toxic for HEK293 and CHO cells. It was therefore not possible to harvest a sufficient amount of mutated PINK1 adenovirus because most of the transfected cells died. Expression of ΔN-PINK1T313M in primary cortical neurons led to abnormal mitochondrial accumulations in the cell soma and retraction of axons and dendrites (Fig. 8A, panels 1–3, arrows). Similar effects were observed even when the cellular microtubules were stabilized by Taxol (Fig. 8B, panels 1–3, arrow). Expression of PINK1FL/T313M in Taxol-treated CHO cells led to the degradation of mitochondria (Fig. 8B, panels 4–6, arrow). This mutant is not inactive and can still be phosphorylated by MARK2 (see Fig. 4A), explaining its toxicity. The quantification of viable transfected cells confirms these results. The survival rate drops to 40% in the case of PINK1FL/T313M and to 6% in the case of ΔN-PINK1T313M expression compared with the expression of the non-mutated form (see Fig. 8C). The T313E mutant was toxic to cells both for full-length and truncated PINK1 because this mutant showed a higher activity in combination with its activating kinase MARK2 (see Fig. 4, A and B).

**DISCUSSION**

This report describes the interaction of two protein kinases, MARK2 and PINK1, both of which are implicated in neurodegenerative diseases (Alzheimer disease and PD). One of the main known functions of MARK2 is to phosphorylate tau and detach it from microtubules. This is an early event in Alzheimer disease, suggesting that overactivation of MARK2 might play a role in the breakdown of microtubules and the interruption of axonal transport (39). Conversely, in neurons with tau elevated by transfection, MARK2 can rescue transport inhibition by phosphorylating and detaching tau from microtubules (1). To analyze the MARK2 signaling pathways in greater detail, we set out to identify new regulatory partners of MARK2. One conspicuous hit was PINK1, a mitochondrially targeted serine/threonine kinase with neuroprotective features (9, 10). Loss-of-function mutations in the PINK1 gene result in recessive heritable forms of parkinsonism (40). Recent studies have shown that PINK1 plays a crucial role in the regulation of mitochondrial dynamics, transport, and function (12, 41). Upon entry into mitochondria, full-length PINK1 protein can be cleaved by voltage-sensitive proteolysis (42). The most stable cleavage product is the 45-kDa fragment, corresponding roughly to ΔN-PINK1 (25). Cytoplasmic actions of ΔN-PINK1 are critical for cell survival because expression of ΔN-PINK1 protects neurons against the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridin (23). However, the mechanism of this ΔN-PINK1 function is unknown. A major limitation in understanding the different functions of this protein kinase with dual localization is the lack of reliable PINK1 antibodies and low levels of endogenous expression (43).
**MARK2 and PINK1 Regulate Mitochondrial Transport**

Therefore, much of the existing data has been based on the expression of tagged, exogenous PINK1.

We found an interaction of MARK2 especially with ΔN-PINK1 that is based on their catalytic domains (Fig. 1B). Consistent with this, primary cortical neurons show colocalization of overexpressed ΔN-PINK1 and MARK2 in dotted structures in axons and dendrites identified as mitochondria (Figs. 2 and 5A). PINK1FL is predominantly localized in the mitochondrial outer membrane with the kinase domain facing the cytoplasm (24), allowing binding and potentially further modification of PINK1FL by MARK2.

Nevertheless, the questions arose why several cleavage fragments of PINK1 are found in different cell compartments and how they become active. Recent studies suggest that PINK1FL is active in the PINK1/Parkin pathway (Fig. 1B). Parkin is a cytoplasmic E3 ubiquitin ligase and can be phosphorylated by PINK1FL (44). Both proteins cooperate to control mitochondrial clearance, known as mitophagy (for reviews, see Refs. 38 and 45 and see Ref. 46). However, neither the exact molecular mechanism how PINK1 recruits Parkin nor the possible role of Parkin phosphorylation are known in detail.

The interaction of MARK2 with ΔN-PINK1 and PINK1FL has distinct consequences for their kinase activities in vitro. MARK2 phosphorylates and activates preferentially ΔN-PINK1 (Figs. 3A and 4, A and B). In the case of PINK1FL, its interaction with MARK2 during the phosphorylation reaction was too transient to be detectable by coimmunoprecipitation, but it could be observed with the non-phosphorylatable mutant PINK1FL/T313M, which locks the two partners in an inactive complex (an analogous situation was observed previously for the interaction between MARK2 and PAK5 (6)). In addition, MARK2 induced the phosphorylation of PINK1FL in transfected CHO cells (supplemental Fig. S1). Phosphopeptide mapping followed by mass spectrometry analysis revealed that MARK2-dependent phosphorylation of ΔN-PINK1 occurs mainly at residue Thr-313, which lies in the kinase domain and possibly leads to a stabilization of the scaffold that fixes the Mg-ATP, a requirement for the activity of the kinase (Fig. 3C). The mutation T313M in PINK1 is associated with familial PD (26); although mutation of this site to alanine decreased the phosphorylation of ΔN-PINK1 by MARK2, it was not completely abolished (Fig. 4A, lane 9), and activation could still occur (Fig. 4B, lane 9), probably via conformational changes and phosphorylation of additional sites (Fig. 3B). However, mutation of Thr-313 to glutamate further enhanced the phosphorylation and activation of ΔN-PINK1 by MARK2 (Fig. 4, A, lane 8, and B, lane 8). Thr-313 could be a priming phosphorylation site, changing the conformation of the kinase and preparing it for further modifications. The importance of this PINK1 phosphorylation site is further emphasized by the directions become comparable (red bars 2 and 3). This effect is further enhanced by MARK2WT because cotransfection of MARK2WT and PINK1FL changes the retrograde value to 80% (red bar 4). Cotransfection of MARK2WT and ΔN-PINK1 increases the anterograde mitochondrial movement (blue bar 6). Thus, MARK2WT amplifies the opposing effects of PINK1FL and ΔN-PINK1 (red boxed areas). D, ratios of anterograde versus retrograde mitochondrial movements shown in logarithmic scale. p values of <0.05 and <0.01 are indicated with one and two asterisks, respectively.

![FIGURE 7. Analysis of mitochondrial movement in RGC axons 24 h after transfection with PINK1FL, ΔN-PINK1, or MARK2WT by adenovirus.](image-url)
fact that expression of PINK1 (T313E) showed severe toxicity for cells (both CHO and neuronal cells). Mutation of the phosphorylation site to Met led to abnormal mitochondrial accumulations in the cell soma (ΔN-PINK1T313M; Fig. 8B, panel 2, arrow) or degradation of mitochondria (PINK1FL/T313M, Fig. 8B, panel 5, arrow). The data argue that MARK2 is an upstream regulator of ΔN-PINK1 and suggest that failure of this cascade contributes to the development of PD. The mutation could also have effects on known PINK1 substrates like Omi/HtrA2 or TRAP-1 (22, 30), but it is questionable whether these proteins are phosphorylated by ΔN-PINK1 under physiological conditions because both are mitochondrial and not cytoplasmic.

Within neurons, endogenous PINK1 and MARK2 partly colocalize on mitochondria, especially in axons and dendrites (Fig. 5, A and C, and supplemental Fig. S2). Fractionation studies revealed that endogenous MARK is found in the mitochondrial fraction of N2a cells (Fig. 5B). From these findings, we hypothesize that MARK2 may be recruited to mitochondria via ΔN-PINK1 and/or PINK1FL. This would alter the mitochondrial distribution because MARK2 in combination with PINK1 changes mitochondrial transport parameters (Figs. 5–7). New aspects on the relationship between PINK1 and mitochondrial transport regulation have been published recently (47). PINK1 phosphorylates the GTPase Miro, a component of a kinesin-adaptor complex, and thus induces its Parkin-dependent degradation. The resulting decrease in mitochondrial movement may represent a quality control mechanism of defective mitochondria (47). In our hands, particularly ΔN-PINK1 induced an arrest of mitochondrial motility, which was even further enhanced by MARK2 coexpression (Fig. 7B). In addition, ΔN-PINK1 increased anterograde movement and eventually led to enhanced mitochondrial density in axons. MARK2 reinforced this effect, possibly by phosphorylation and activation of ΔN-PINK1. Consistent with this, a high membrane potential promotes the anterograde transport of mitochondria (48) and also promotes the proteolysis of full-length PINK1 into ΔN-PINK1 (42). Conversely, retrograde transport is favored for mitochondria with low membrane potential destined for mitophagy (49); in this case, the cleavage of PINK1FL is inhibited in agreement with the transport characteristics induced by PINK1FL + MARK2 (Fig. 7). Mounting evidence indicates that Parkin is recruited via PINK1FL to defective mitochondria, inducing their degradation (for a review, see Ref. 50). Thus, Parkin-decorated mitochondria assemble as large clusters primarily in the lysosome-rich perinuclear area (42, 51). This effect seems to be influenced by MARK2 (Fig. 7, C and D). MARK2 could phosphorylate PINK1FL and consequently enhance the binding and possibly the phosphorylation of Parkin and Miro by PINK1FL. This is also suggested by the results of a protein stability assay. MARK2T208/S212A enhanced particularly the stability of PINK1FL (Fig. 4D). Conversely, healthy mitochondria promote the cleavage of PINK1FL, leading to high levels of ΔN-PINK1, which is not able to translocate Parkin to impaired mitochondria (51). This suppresses mitophagy and could explain why mitochondria accumulate in the cell soma of ΔN-PINK1T313M-transfected cells (Fig. 8).

Mitochondria are transported along microtubules by motor proteins kinesin (forward) and dynein (reverse). The kinesin-adaptor complex attached to the outer membrane comprises the GTPase Miro, kinesin heavy chain, and the adaptor protein Milton (52). PINK1FL is also attached to this complex, and even ΔN-PINK1 can be targeted to it despite the lack of the mitochondrial targeting sequence (24, 36). These observations argue that ΔN-PINK1 can participate in the control of anterograde mitochondrial trafficking and influence kinesin indirectly via Milton, consistent with the enhanced anterograde transport in cells overexpressing ΔN-PINK1 (Fig. 7, C and D).
This assumption is supported by the observation that PINK1ΔMTS (equivalent to our ΔN-PINK1) has much stronger effects on anterograde transport compared with the retrograde transport of mitochondria (47).

In summary, our results suggest a model with PINK1 as a molecular switch between anterograde and retrograde mitochondrial transport (Fig. 9). A related mechanism has been shown for huntingtin, which controls the direction of vesicular transport in neurons (53). We propose that transport direction of mitochondria is regulated by PINK1 cleavage dependent on the mitochondrial membrane potential and PINK1 binding/phosphorylation by MARK2. Alterations in mitochondrial homeostasis have been implicated as an important source of many neurodegenerative diseases. Suppression of PINK1 kinase activity and/or down-regulation of PINK1 transcription contributes to PD pathogenesis, but enhanced PINK1 kinase activity also induces neuronal cell death. A similar relationship was demonstrated recently for the leucine-rich repeat kinase 2 (LRRK2), which is also involved in PD (54). Together, our findings confirm the importance of a tight regulation of PINK1 and demonstrate that PINK1FL and ΔN-PINK1 have distinct functions regarding mitochondrial transport, depending on MARK2.

Acknowledgments—We are grateful to Jacek Biernat for adenoviral constructs of MARK2 and PINK1; Edye Thies for introduction to primary cell culture and mitochondrial transport experiments; Alexander Marx for help with data analysis; Cindy Johne for some PINK1 constructs; Xiaoyu Li for help with confocal microscopy; Yipeng Wang, Ulrike Krüger, Konstanze Winklohofer (University of Munich), and Eckhard Mandelkow for discussions during this work; and Sabrina Hübßmann for excellent technical assistance. We thank P. Seubert (Elan Pharmaceuticals, South San Francisco, CA) for providing the 12E8 antibody and A. M. Cuervo (Albert Einstein College, Bronx, NY) for providing preparations of subcellular fractions from N2A cells.

REFERENCES

1. Thies, E., and Mandelkow, E. M. (2007) Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1. J. Neurosci. 27, 2896–2907
2. Matenia, D., and Mandelkow, E. M. (2009) The tau of MARK: a polarized view of the cytoskeleton. Trends Biochem. Sci. 34, 322–342
3. Timm, T., Li, X. Y., Biernat, J., Ioa, I., Mandelkow, E., Vandenkocerkhove, J., and Mandelkow, E. M. (2003) MARK, a Ste20-like kinase, activates the polarity-inducing kinase MARK/Par-1. EMBO J. 22, 5090–5101
4. Timm, T., Balusamy, K., Li, X., Biernat, J., Mandelkow, E., and Mandelkow, E. M. (2008) Glycogen synthase kinase (GSK) 3β directly phosphorylates Serine 212 in the regulatory loop and inhibits microtubule affinity-regulating kinase (MARK) 2. J. Biol. Chem. 283, 18873–18882
5. Liczano, J. M., Göransson, O., Toth, R., Deak, M., Morrice, N. A., Boudou, J., Hawley, S. A., Udd, L., Mikeli, T. P., Hardie, D. G., and Alessi, D. R. (2004) LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/Par-1. EMBO J. 23, 833–843
6. Matenia, D., Griesshaver, B., Li, X. Y., Thiessen, A., Johne, C., Ioa, I., Mandelkow, E., and Mandelkow, E. M. (2005) PAK5 kinase is an inhibitor of MARK/Par-1, which leads to stable microtubules and dynamic actin. Mol. Biol. Cell 16, 4410–4422
7. Elbert, M., Rossi, G., and Brenwald, P. (2005) The yeast par-1 homologs kin1 and kin2 show genetic and physical interactions with components of the exocytic machinery. Mol. Biol. Cell 16, 532–549
8. Panneerselvam, S., Marx, A., Mandelkow, E. M., and Mandelkow, E. (2006) Structure of the catalytic and ubiquitin-associated domains of the protein kinase MARK/Par-1. Structure 14, 173–183
9. Deng, H., Iankovic, J., Guo, Y., Xie, W., and Le, W. (2005) Small interfering RNA targeting the PINK1 induces apoptosis in dopaminergic cells SH-SY5Y. Biochem. Biophys. Res. Commun. 337, 1133–1138
10. Valente, E. M., Abou-Sleiman, P. M., Caputo, Y., Muqit, M. M., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., Albanese, A., Nussbaum, R., González-Maldonado, R., Deller, T., Salvi, S., Cortelli, P., Gilks, W. P., Latchman, D. S., Harvey, R. J., Dallapiccola, B., Auburger, G., and Wood, N. W. (2004) Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science 304, 1158–1160
11. Wood-Kaczmar, A., Gandhi, S., Yao, Z., Abramov, A. Y., Abramov, A. S., Miljan, E. A., Keen, G., Stanyer, L., Hargreaves, I., Klupsch, K., Deas, E., Downward, J., Mansfield, L., Jat, P., Taylor, J., Heales, S., Duchen, M. R., Latchman, D., Tabrizi, S. J., and Wood, N. W. (2008) PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons. PLoS One 3, e2455
12. Deas, E., Plun-Favreau, H., and Wood, N. W. (2009) PINK1 function in health and disease. EMBO Mol. Med. 1, 152–165
13. Pogson, J. H., Ivatt, R. M., and Whitworth, A. J. (2011) Molecular mechanisms of PINK1-related neurodegeneration. Curr. Neurol. Neurosci. Rep. 11, 283–290
14. Bellina, A., Van Der Brug, M., Ahmad, R., Kesavapany, S., Miller, D. W., Petsko, G. A., and Cookson, M. R. (2005) Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability. Proc. Natl. Acad. Sci. U.S.A. 102, 5703–5708
15. Weihofen, A., Ostaszewski, B., Minami, Y., and Sellke, D. J. (2008) PINK1 Parkinson mutations, the Cdc37/Hsp90 chaperones and Parkin all influence the maturation or subcellular distribution of PINK1. Hum. Mol. Genet. 17, 602–616
16. Clark, I. E., Dodson, M. W., Jiang, C., Cao, J. H., Huh, J. R., Seol, J. H., Yoo, S. J., Hay, B. A., and Guo, M. (2006) Drosophila parkin is required for mitochondrial function and interacts genetically with parkin. Nature 441, 1162–1166
17. Exner, N., Treske, B., Paquet, D., Holmström, K., Schiesling, C., Gispert, S., Carballo-Carbajal, I., Berg, D., Hoepken, H. H., Gasser, T., Krüger, R., Winklohofer, K. F., Vogel, F., Reichert, A. S., Auburger, G., Kahle, P. J., Schmid, and Haass, C. (2007) Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J. Neurosci. 27, 12413–12418
18. Gautier, C. A., Kitada, T., and Shen, J. (2008) Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress.
MARK2 and PINK1 Regulate Mitochondrial Transport

Proc. Natl. Acad. Sci. U.S.A. 105, 11368–11369
19. Park, J., Lee, S. B., Lee, S., Kim, Y., Song, S., Kim, S., Bae, E., Kim, J., Shong, M., Kim, J. M., and Chung, J. (2006) Mitochondrial dysfunction in Drsophila PINK1 mutants is complemented by parkin. Nature 441, 1157–1161
20. Poole, A. C., Thomas, R. E., Andrews, L. A., McBride, H. M., Whitworth, A. J., and Pallenck, L. J. (2008) The PINK1/Parkin pathway regulates mitochondrial morphology. Proc. Natl. Acad. Sci. U.S.A. 105, 1638–1643
21. Gandhi, S., Muqit, M. M., Stanyer, L., Healy, D. G., Abou-Sleiman, P. M., Dauer, W., and Cheng, H. C. (2008) C-terminal truncation and Parkinson's disease-motor neurons and enhances oxidative stress. Acta Neuropathol. 105, 1051–1063
22. Poole, A. C., Thomas, R. E., Andrews, L. A., McBride, H. M., Whitworth, A. J., and Springer, W. (2010) PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Curr. Opin. Neurobiol. 20, 2355–2367
23. Schmitt-Ulms, G., Matenia, D., Drewes, G., and Mandelkow, E. M. (2009) Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. 117, 495–503
24. Goldstein, A. Y., Wang, X., and Schwarz, T. L. (2008) Axonal transport and proteolytic destabilization by PARL. J. Cell Biol. 191, 933–942
25. Boyle, W. J., van der Geer, P., and Hunter, T. (1991) Phosphopeptide mapping and phosphoamino acid analysis by two-dimensional separation on thin-layer cellulose plates. Methods Enzymol. 201, 110–149
26. Geisler, S., Holmström, K. M., Skujat, D., Fiesel, F. C., Rothfuss, O. C., Kahle, P. J., and Springer, W. (2010) PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Curr. Opin. Neurobiol. 20, 2355–2367
27. Trinczek, B., Ebneht, A., Mandelkow, E. M., and Mandelkow, E. (1997) MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption. Cell 89, 297–308
28. Zeisset, L., Caputo, V., Bellacchio, E., Atorino, L., Dallapiccola, B., Valente, E. M., and Casari, G. (2005) Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum. Mol. Genet. 14, 817, 119–121
29. Deas, E., Wood, N. W., and Plun-Favreau, H. (2011) Mitophagy and Parkinson's disease: the PINK1–parkin link. Biochem. Biophys. Acta 1813, 623–633
30. Wang, X., Winter, D., Ashrafi, G., Schlehe, J., Wong, Y. L., Selkoe, D., Rice, S., Steen, J., Lavoie, M. J., and Schwarz, T. L. (2011) PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. Cell 147, 893–906
31. Miller, K. E., and Sheetz, M. P. (2004) Axonal transport defects and potential are correlated. J. Cell Sci. 117, 2791–2804
32. Jin, S. M., Lazarou, M., Wang, C., Kane, L. A., Naredra, D. P., and Youle, R. J. (2010) Mitochondrial membrane potential regulates PINK1 import and proteolytic destabilization by PARL. J. Cell Biol. 191, 933–942
33. Vives-Bauza, C., and Przedborski, S. (2011) Mitophagy: the latest problem for Parkinson's disease. Trends Mol. Med. 17, 158–165
34. Geisler, S., Holmström, K. M., Skujat, D., Fiesel, F. C., Rothfuss, O. C., Kahle, P. J., and Springer, W. (2010) PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nature Cell Biol. 12, 119–131
35. Goldstein, A. Y., Wang, X., and Schwarz, T. L. (2008) Axonal transport and the delivery of pre-synaptic components. Curr. Opin. Neurobiol. 18, 495–503
36. Colín, E., Zala, D., Liot, G., Rangone, H., Borrell-Pagès, M., Li, X. J., Sauvan, E., Brumaghim, L., and Zinsmaier, K. E. (2009) Drosophila Miro is required for both anterograde and retrograde axonal mitochondrial transport. J. Neurosci. 29, 5443–5455